title: XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer.
abstract: OBJECTIVE
  The efficacy and tolerability of oxaliplatin in combination with either folinic acid, fluoro-uracil (5-FU) (FOLFOX4 regimen) or capecitabine (XE-LOX regimen) was evaluated in advanced pancreatic cancer.
  
  
  METHODS
  In this study, eighty-five patients with advanced pancreatic cancer were enrolled after failing to gemcitabine-based chemotherapy between November 2005 and August 2011. FOLFOX4 was repeated every two weeks and XELOX regimen was repeated every three weeks until either disease progression or unacceptable toxicity occurred.
  
  
  RESULTS
  Eighty-five patients were evaluated for tumor response.Seven patients (18%) achieved a partial response with XELOX and stable disease was observed in 16 patients (41%). Eight patients (17%) achieved a partial response with FOLFOX4 and stable disease was observed in 12 patients (26%). Disease control rates were 59%in the XELOX arm and 43% in the FOLFOX4 arm. The median time to progression was 16 weeks in both arms.The median overall survival was 21 weeks with XELOX and 25 weeks with FOLFOX4.
  
  
  CONCLUSIONS
  Oxaliplatin-based combination therapy showed moderate clinical activity with acceptable toxicity in patients who had progressive disease after receiving gemcitabine-based chemotherapy for advanced and/or metastatic pancreatic cancer. We conclude that XELOX is similar in terms of efficacy and toxicity profile to FOLFOX4 in the sec-ond-line treatment of metastatic pancreatic cancer.
authors.affiliation: Dept. of Medical Oncology, Erciyes University Medical Faculty, M. Kemal Dedeman Oncology Hospital, Kayseri, Turkey. veliberk@gmail.com
authors.forename: Veli
authors.initials: V
authors.lastname: Berk
authors.forename: Nuriye
authors.initials: N
authors.lastname: Ozdemir
authors.forename: Metin
authors.initials: M
authors.lastname: Ozkan
authors.forename: Sercan
authors.initials: S
authors.lastname: Aksoy
authors.forename: Nedim
authors.initials: N
authors.lastname: Turan
authors.forename: Ali
authors.initials: A
authors.lastname: Inal
authors.forename: Ozan
authors.initials: O
authors.lastname: Balakan
authors.forename: Nurgul
authors.initials: N
authors.lastname: Yasar
authors.forename: Olcun Umit
authors.initials: OU
authors.lastname: Unal
authors.forename: Mustafa
authors.initials: M
authors.lastname: Benekli
authors.forename: Ayse
authors.initials: A
authors.lastname: Durnali
authors.forename: Dilsen
authors.initials: D
authors.lastname: Colak
authors.forename: Ozlem Uysal
authors.initials: OU
authors.lastname: Sonmez
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D053208:Kaplan-Meier Estimate; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D010071:Oxaloacetates; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012189:Retrospective Studies; D013997:Time Factors; D017211:Treatment Failure; D014421:Turkey; D000093542:Gemcitabine
chemical_list: D009944:Organoplatinum Compounds; D010071:Oxaloacetates; D003841:Deoxycytidine; D000069287:Capecitabine; D002955:Leucovorin; D005472:Fluorouracil; D000093542:Gemcitabine